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Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage 
matrix. Due to lack of effective treatment for advanced disease, the clinical management 
of chondrosarcomas is exceptionally challenging. Current research focuses on elucidating 
the molecular events underlying the pathogenesis of this rare bone malignancy, with the 
goal of developing new molecularly targeted therapies. Signaling pathways suggested to 
have a role in chondrosarcoma include Hedgehog, Src, PI3k–Akt–mTOR and angiogenesis. 
Mutations in IDH1/2, present in more than 50% of primary conventional chondrosarcomas, 
make the development of IDH inhibitors a promising treatment option. The present review 
discusses the preclinical and early clinical data on novel targeted therapeutic approaches in 
chondrosarcoma.
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Chondrosarcoma is a malignant tumor of bone that is characterized by the production of carti-
lage matrix by tumor cells but displays diverse histopathology and clinical behavior [1]. Following 
osteosarcoma, it is the second most frequent primary malignant tumor of bone [2], accounting 
for 20–27% of primary malignant bone neoplasms [3]. The most common anatomical location of 
origin is pelvis, followed by the proximal femur, proximal humerus, distal femur and ribs [4]. The 
vast majority (90%) are conventional chondrosarcomas, either presenting de novo in the medulla of 
bone, or arising as a secondary tumor from pre-existing benign lesion such as enchondromas and 
osteochondromas. The remaining 10% are rare variants of chondrosarcoma, which include dedif-
ferentiated, clear cell and mesenchymal chondrosarcomas. It remains a matter of debate whether 
myxoid chondrosarcoma represents a higher grade variant of conventional chondrosarcoma or 
should be considered a distinct disease entity [5]. Conventional chondrosarcomas are typically low 
or intermediate grade and are characterized by indolent clinical course and low metastatic potential. 
High-grade chondrosarcomas account for 5–10% of conventional chondrosarcomas and are associ-
ated with high metastatic potential and poor prognosis. The main site of metastatic disease is lung, 
while the regional lymph nodes and liver are much less commonly involved [6,7].
The cornerstone of the management of localized chondrosarcomas is surgical resection. Low-
grade tumors confined to the bone, in selected cases can be managed by extensive intralesional 
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curettage, with the aim of minimizing func-
tional disability [8,9], while high-grade tumors 
require wide, en-bloc local excision with nega-
tive margins [10]. The adequate surgical margin 
for low-grade intracompartmental chondro-
sarcomas is a matter of controversy, as some 
surgeons propose wide resection, while others 
believe that intralesional resection, followed by 
adjuvants, such as liquid nitrogen, phenol, cryo-
therapy, electrocautery and argon-beam laser is 
adequate [11]. Chondrosarcomas are inherently 
resistant to conventional chemo and radiation 
therapy. Proposed mechanisms of chemoresist-
ance include low mitotic fraction and restricted 
drug penetration into tumor microenvironment 
as a result of poor vascularity and abundant hya-
line-dense extracellular matrix [1,12]. The pos-
sible activation of multidrug resistance pumps 
and the increased expression of antiapoptotic 
factors have also been described to contribute 
to chemotherapy resistance [12,13]. However, 
some of the rare subtypes may be more respon-
sive [12], for example, mesenchymal chondrosar-
comas have been demonstrated to be sensitive to 
doxorubicin-based combination chemotherapy, 
based on modest clinical evidence from non-
randomized trials [14]. Stereotactic radiosurgery 
has been successfully employed for skull-base 
and spinal chondrosarcomas and proton radio-
therapy has been used for chondrosarcoma of 
the skull base and cervical spine [15]. Likewise, 
retrospective evidence suggests that dedifferenti-
ated chondrosarcoma managed with combina-
tion of surgery and chemotherapy may have a 
better outcome than those treated with surgery 
alone [16].
Due to the limited efficacy of available treat-
ments, the clinical management of chondro-
sarcomas is challenging, and new therapeu-
tic approaches are urgently needed. Current 
research focuses on elucidating the molecular 
events underlying the pathogenesis of this rare 
bone malignancy, aiming at the identification 
of new molecularly-targeted therapies, espe-
cially for chemotherapy refractory, inoperable 
or metastatic chondrosarcomas. Our objective 
in this review is to discuss the current research 
of pharmaceutical targets for novel therapeutic 
interventions (Figure 1).
The emerging role of IDH mutations in 
chondrosarcoma
Over the last few years, growing evidence 
suggests that certain oncogenic alterations in 
pathways directly reprogram the metabolic 
activity of the cancer cell [17,18]. One of the best 
described genetic alterations linking oncogen-
esis and metabolism are mutations in the IDH1 
and IDH2 genes. IDH proteins, encoded by the 
IDH genes, catalyze the oxidative decarboxyla-
tion of isocitrate, producing αKG and CO2 in 
the Krebs cycle. Mutations in the IDH family 
of genes have been described in patients with 
a variety of cancers [19,20]. These mutations are 
known to produce 2HG from αKG conversion. 
2HG accumulates in the serum of the patients 
and inhibits the function of enzymes that are 
dependent on αKG, leading to a hypermethyl-
ated state of DNA and histones, which results 
in different gene expression associated with 
tumorigenesis [20]. 2HG inhibits TET2 activity 
in vitro, which is a member of the TET family of 
αKG-dependent DNA modifying enzymes, and 
a DNA demethylation mediator. Thus, 2HG 
results in DNA hypermethylation, by inhibiting 
TET2-mediated DNA demethylation. 2HG also 
inhibits αKG-dependent JHKDMs. JHKDMs 
modify chromatin to regulate gene expression 
epigenetically. These enzymes, considered as 
tumor suppressors, have been associated with 
oncogenesis in various types of cancer [21].
Somatic mutations of the IDH genes are pre-
sent in around 87% of benign enchondromas 
and more than 50% of primary conventional 
chondrosarcomas [5,22]. These mutations have 
been linked to the enchondromatosis-associated 
nonhereditary Maffucci and Ollier syndromes. 
The high mutation frequency in enchondromas 
and the fact that they are early events suggest 
a causal role for IDH1 or IDH2 mutations in 
tumorigenesis in Ollier disease and Maffucci 
syndrome [23,24].
IDH2 mutation has been shown to induce 
2HG-dependent DNA hypermethylation in 
chondrosarcoma cells, resulting in inhibition of 
mesenchymal differentiation through epigenetic 
dysregulation. Treatment with the demethylat-
ing agent 5-azacytidine reversed this differen-
tiation block, suggesting a potential route for 
therapeutic development [25]. Treatment of cells 
with AGI-5198, a specific inhibitor of mutant 
IDH1, has been shown to reduce production 
of 2-HG by up to 90% across a number of 
chondrosarcoma cell lines harboring endog-
enous IDH1 mutation. However, the effect of 
IDH1 inhibition on viability, proliferation and 
migration on these cells has been inconsistent 
between studies, suggesting there is further 
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complexity to the role of epigenetic d ysregulation 
in chondrosarcoma [26,27].
Ongoing clinical trials are evaluating the clin-
ical activity of novel IDH inhibitors. AG-221, an 
oral IDH2 inhibitor, is currently being tested 
in a Phase I/II, multicenter trial enrolling 
patients with advanced solid tumors, including 
glioma, angioimmunoblastic T-cell lymphoma 
and chondrosarcoma with an IDH2 mutation 
(NCT02273739). The IDH inhibitors AG-881 
and AG-120 are also under clinical evaluation 
in Phase I studies of advanced solid tumors that 
harbor an IDH1 and/or IDH2 mutation, includ-
ing gliomas, cholangiocarcinomas and chondro-
sarcomas (NCT02481154/NCT02073994). 
Moreover, there is an ongoing Phase Ib, open-
label, single-center, nonrandomized clinical 
trial that evaluates the toxicity and efficacy of 
metformin in combination with chloroquine in 
IDH1/2 mutated patients with a glioma, intra-
hepatic cholangiocarcinoma or chondrosarcoma 
(NCT02496741). Based on the data described 
above, the development of IDH inhibitors is 
emerging as a promising treatment option on 
the horizon for patients with chondrosarcoma.
Targeting the hedgehog pathway
The Hedgehog signaling pathway is an impor-
tant regulator of cell growth and differentiation 
during embryogenesis and is also involved in the 
maintenance of homeostasis in postembryonic 
tissues by regulating the differentiation of stem 
cells [28]. When extracellular hedgehog ligands 
binds to PTCH1, a transmembrane receptor, 
PTCH1-mediated inhibition of signaling by 
SMO is prevented [29]. Activation of the SMO 
results in the activation of transcription factors 
encoded by GLI family zinc finger and con-
sequent expression of hedgehog target genes, 
including GLI1 and PTCH1 [30].
The Indian Hedgehog (IHH)/parathyroid 
hormone-related peptide pathway (PTHrP) has 
a crucial role to chondrocyte differentiation and 
emerging evidence proposes that constitutive 
IHH signaling has a key role in the pathogen-
esis of chondrosarcomas [31]. Aberrant activation 
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of this pathway leads to constant signals from 
IHH, which induce chondrocyte proliferation 
and secretion of PTHrP from chondrocytes to 
the perichondrial space. There, PTHrP medi-
ates inhibition of chondrocyte differentiation 
and apoptosis, therefore maintaining the cells 
in their proliferative state. The deregulation of 
the pathway also leads to high expression levels 
of its intramembrane receptor PTCH1 and its 
downstream transcription factor GLI [31].
A recent study evaluated in primary chon-
drosarcoma xenografts the activity of IPI-926, 
a potent oral Hh-inhibitor, on tumor formation 
and growth. The results demonstrated that IPI-
926 had significant antitumor effects against 
human chondrosarcoma cell lines [32]. IPI-926 
had previously shown activity in xenograft mod-
els of basal cell carcinoma and medulloblastoma, 
tumors which are also dependent on constitu-
tive Hh signaling [32,33]. In another study, treat-
ment of human chondrosarcoma SW1353 cells 
with the HH pathway inhibitor-4 (HPI-4) sig-
nificantly decreased proliferation, invasion and 
migration capacity [34]. An additional study 
demonstrated that knockdown of GLI1 expres-
sion by siRNA downregulated the expression of 
key Hh pathway members, including PTCH1 
and SMO, and restrained the growth and sur-
vival of the treated chondrosarcoma cells [35]. 
The results of these studies provide the rationale 
for investigating Hh pathway blockade as a novel 
therapeutic option for patients with chondrosar-
coma presenting aberrant activation of the HH 
signaling pathway.
While preclinical data of IPI-926 (saridegib) 
have demonstrated activity in a wide range of 
malignancies, the clinical data of a Phase II 
randomized placebo-controlled trial in patients 
with advanced chondrosarcoma have been 
discouraging [36]. Likewise, treatment with 
GDC-0449 (vismodegib) tested in a single-arm 
Phase II trial, although suggesting some activity 
in a subset of patients with progressive grade 1 
or 2 conventional chondrosarcoma, did not meet 
the primary end point of 6-month clinical ben-
efit rate [37]. These disappointing clinical results 
may indicate a ligand-independent activation 
of the Hh pathway in chondrosarcoma, which 
might occur with loss-of-function mutation of 
PTCH or gain-of-function mutation of SMO. 
Surrogate markers for selection of patients more 
likely to benefit from such targeted treatments 
could lead to more favorable outcomes in future 
studies [37].
The SRC pathway
Src and other members of the Src family of pro-
tein tyrosine kinases play key roles in regulating 
the transduction of signals originating from cell 
surface receptors [38,39]. The activation of the c-Src 
pathway has been observed in several tumors 
and has been linked to intratumoral signaling 
involved in cell survival, angiogenesis, prolifera-
tion and migration [39,40]. The Src was found to be 
activated in human sarcoma tissues (leiomyosar-
coma, high-grade osteosarcoma) and sarcoma cell 
lines (osteosarcoma, Ewing’s sarcoma, rhabdo-
myosarcoma) [41], while in synovial sarcoma cells 
it has been identified as one of the most strongly 
phosphorylated kinases [42]. Thereby, Src has been 
proposed to play an important role in signal trans-
duction in human sarcomas, including osteosar-
coma, rhabdomyosarcoma, l eiomyosarcoma, 
fibrosarcoma and Ewing sarcoma [43].
Based on these findings, Src became an entic-
ing target for drug development and a number of 
Src inhibitors, including dasatinib (BMS354825) 
are currently at various stages in the development 
process [44]. Dasatinib is a small molecule inhibi-
tor that targets a broad range of tyrosine kinases, 
including ABL, SRC family kinases, c-KIT and 
PDGFR-α and -β [45]. Inhibition of the Src path-
way by dasatinib in sarcoma cell lines demon-
strated therapeutic benefit, preventing the growth 
and metastasis [41,46], while in another study it 
resulted in decreased cell viability in seven of nine 
chondrosarcoma cell cultures [46].
Although dasatinib as a single agent has 
shown some preclinical activity in chondrosar-
comas, there is an accumulating body of evi-
dence to support the use of dasatinib in com-
bination with other antineoplastic drugs [47–50]. 
Oosterwijk et al. showed that dasatinib was 
effective in overcoming chemoresistance and 
successfully sensitized chondrosarcoma for doxo-
rubicin treatment, especially in TP53 mutant 
chondrosarcoma cell lines [51]. On the contrary, 
the SARC009 trial, a Phase II study of dasatinib 
in patients with previously treated, high-grade, 
advanced sarcomas, including chondrosarcomas 
concluded that dasatinib was inactive as a sin-
gle agent [52]. Thus, Src inhibitors might offer 
a new approach in the treatment of sarcoma 
in c ombination with other chemotherapeutic 
regimens.
Targeting the PI3K–Akt–mTOR pathway
The PI3K–Akt–mTOR pathway has a signifi-
cant role in various normal cellular processes 
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including cell proliferation, growth and sur-
vival [53]. The activation of the pathway is ini-
tiated by ligand activation of receptor tyros-
ine kinases (RTKs), such as the IGF-1R and 
PDGFR-α and -β. Aberrant activation of the 
PI3K pathway has been implicated in tumori-
genesis of various cancers, and increased acti-
vation of this pathway is often associated with 
resistance to cytotoxic therapies [54,55]. Due to 
these observations and its critical contribution in 
cell growth and survival, this pathway became 
a promising target for pharmacologic interven-
tion. The rapamycin analogs everolimus and 
temsirolimus, which inhibit mTORC1, were the 
first PI3K pathway-targeted agents approved for 
the treatment of renal cancer. Subsequently, an 
increasing number of PI3K pathway inhibitors 
have undergone clinical evaluation [56].
In a recent study, multiple RTKs were found 
to be activated in chondrosarcoma cells and to 
exhibit crucial roles in mediating cell growth [57]. 
Strong phosphorylation of S6 kinase, a surrogate 
of PI3K–mTOR pathway activity, was detected 
in 69% of conventional chondrosarcoma and 
44% of dedifferentiated chondrosarcoma clini-
cal samples, suggesting that activation of the 
PI3K–Akt–mTOR pathway in cell lines is clini-
cally relevant. The study links RTK activation 
in chondrosarcoma cells to PI3K–Akt–mTOR 
signaling by showing that RTK inhibitors 
suppress Akt and S6 kinase phosphorylation. 
Treatment with BEZ235, a dual PI3K/mTOR 
inhibitor, significantly reduced the growth of 
chondrosarcoma cell lines and in a xenograft 
model of chondrosarcoma, suggesting that inhi-
bition of the PI3K/mTOR pathway represents a 
rational therapeutic strategy [57].
Another study investigated the antitumor 
effect of doxorubicin and/or everolimus as a 
single agent or in combination in a rat chon-
drosarcoma model, both in macroscopic and in 
microscopic residual disease following R1 resec-
tion of the implanted tumor [58]. Doxorubicin 
as a single agent was inactive, in terms of inhib-
iting tumor growth, while everolimus had a 
major suppressant effect on tumor progres-
sion in macroscopic tumors and significantly 
delayed or prevented tumor recurrence in rats 
with microscopic residual disease. The combina-
tion with doxorubicin did not exhibit additive 
synergistic effect. These preclinical data support 
the use of mTOR inhibitors as a single agent in 
treating chondrosarcoma patients, and moreo-
ver the use of everolimus as adjuvant long-term 
therapy in chondrosarcoma patients following 
surgery [58]. A retrospective study of ten patients 
with unresectable chondrosarcoma, who were 
treated with the mTOR inhibitor sirolimus in 
combination with cyclophosphamide, showed 
that the regimen was well tolerated with disease 
control rate of 70%, implying meaningful clini-
cal activity [59]. A recently published Phase I/II 
clinical trial evaluated the ability of temsiroli-
mus to potentiate the cytotoxic effect of lipo-
somal doxorubicin [60]. Reported Phase I data 
have demonstrated safety of the combination in 
adult and pediatric patients. The Phase II expan-
sion part of this study is ongoing [60]. A Phase II 
study of everolimus in patients with primary or 
relapsed chondrosarcomas is ongoing, aiming to 
evaluate the efficacy and safety of everolimus as 
neo-adjuvant therapy (NCT02008019).
The IGF-1R-mediated activation of the 
PI3K–Akt pathway is a recognized mecha-
nism of intrinsic mTORC1 inhibitor resistance 
described in a range of malignancies, including 
sarcoma [61–63]. IGF-1R overexpression has been 
reported in a number of sarcoma subtypes [64,65]. 
Preclinical data indicate that combination of 
mTOR with IGF-1R inhibitors results in sup-
pression of Akt activation and enhancement of 
drug-induced antiproliferative effects [63]. This 
knowledge led to the design of several early phase 
clinical trials evaluating the combined mTORC1 
and IGF-1R inhibition in sarcoma patients [66–
68], with early results indicating that the com-
bination may have greater clinical efficacy than 
treatment with each agent alone [67]. PDGFR-α 
is another RTK that can mediate rapamycin-
induced Akt phosphorylation in sarcoma cell 
lines in a subset of tumors, and therefore, could 
be an attractive therapeutic target to inhibit 
in combination with mTORC [69]. Moreover, 
kinome analysis of chondrosarcoma tumors has 
shown that among others, the PDGFR pathway 
is overactive in chondrosarcomas [46].
A Phase II trial of the R1507, an IGF-1R 
inhibitor, enrolled patients with recurrent or 
refractory bone and soft tissue sarcoma and 
demonstrated that R1507 is safe and well toler-
ated but has limited clinical activity [70]. Another 
Phase II study investigated patients with previ-
ously treated advanced or metastatic bone and 
soft tissue sarcomas, treated with the IGF-1R 
inhibitor cixutumumab (IMC-A12), a fully 
human IgG1 monoclonal antibody. The results 
indicated that cixutumumab was well toler-
ated and patients with adipocytic sarcoma may 
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benefit from the treatment [65]. An additional 
Phase I clinical trial is exploring the safety, effi-
cacy and best dose of cixutumumab given in 
combination with doxorubicin in patients with 
unresectable, locally advanced or metastatic soft 
tissue sarcoma (NCT00720174).
The Italian Sarcoma Group enrolled 26 
patients in a Phase II trial of imatinib, a multi 
tyrosine-kinase inhibitor including inhibition 
of PDGFR, in patients with recurrent nonre-
sectable chondrosarcomas, which all demon-
strated immunohistochemical expression of 
PDGFR. Although imatinib was well-tolerated, 
the trial failed to demonstrate meaningful clini-
cal activity [71]. The efficacy of imatinib is also 
under evaluation in the NCT00928525 open-
label trial of Patients with Desmoid Tumors 
and Chondrosarcoma, expressing PDGFR-α 
and -β.
Histone deacetylase inhibitors
Modification of histones by acetylation is a key 
mechanism for the regulation of gene expression 
and plays a central role in determining cellular 
differentiation state. Dysregulation of histone 
modification is commonly found across a broad 
range of cancer types and has emerged as an 
important therapeutic target. The established 
knowledge that epigenetic alterations can change 
gene expression and consequently phenotype, 
disturb homeostasis and contribute to tumor 
growth has made the histone deacetylase inhibi-
tors (HDACIs) an attractive class of anticancer 
therapy [72,73].
The acetylation status of histones, as it alters 
chromatin architecture, has an important role 
in modifying gene expression [72]. Abnormal 
histone acetylation status has been linked to 
the development of various diseases, includ-
ing cancer. Loss of acetylation at Lys16 and 
trimethylation at Lys20 of histone H4 consti-
tutes a c ommon finding in cancer in a variety 
of cancers [73].
Currently, there are four HDACIs approved by 
the US FDA, for the treatment of refractory cuta-
neous T-cell lymphoma (vorinostat/ZOLINZA 
and romidepsin/ISTODAX®), peripheral T-cell 
lymphoma (belinostat/Beleodaq and romidep-
sin) [74–77], relapsed and/or refractory multiple 
myeloma (panobinostat/FARYDAK®), as well as 
several clinical trials investigating novel HDACIs 
in various malignancies (Table 1).
Based on preclinical data showing that 
HDACIs induce growth arrest, apoptosis and 
differentiation in sarcoma cancer stem cells [78], 
as well as in chondrosarcoma cells [79], there 
is a Phase II clinical trial of a single agent 
Romidepsin in metastatic or unresectable soft 
tissue sarcomas (NCT00112463). Compelling 
preclinical work and early signals of clinical effi-
cacy from early phase clinical trials indicate the 
likely worth of continued investigation of this 
class of drugs in chondrosarcoma [80].
The role of angiogenesis
Angiogenesis is a hallmark trait required for can-
cer development, progression and metastasis [81], 
and has proven to be an important therapeutic 
target over the past two decades. There is grow-
ing evidence from preclinical data, implicating 
angiogenesis with the pathogenesis of chondro-
sarcomas [82–86]. In addition, vascularization 
increases with increasing histological grade [87]. 
SU6668 is an inhibitor of the RTKs Flk-1/KDR 
(VEGR2), PDGFR-β and FGFR1. SU6668 
induced a growth inhibition of chondrosarcoma 
animal models, which appears to be linked to the 
antiangiogenic effects of SU6668 [82]. Inhibition 
of COX-2 by celecoxib, a COX-2 inhibitor, 
which is another mediator of angiogenesis, has 
been tested in four high-grade chondrosarcoma 
cell lines. Treatment with celecoxib minimized 
cell viability in vitro. Conventional central and 
peripheral cartilaginous tumors from 66 patients 
were immunohistochemically assessed for COX-2 
protein expression and 65% were found positive. 
The initial response in tumor growth supported 
a role for celecoxib, although a relapse in tumor 
growth was noticed after 6 weeks of treatment [88].
The NCT01330966 Phase II study is inves-
tigating the efficacy and safety of the single 
agent pazopanib in patients with unresectable 
or metastatic chondrosarcoma. Pazopanib is a 
potent and selective multitargeted RTK inhibi-
tor, which inhibits c-KIT, FGFR, PDGFR and 
VEGFR among other enzymes [89]. Additionally, 
the NCT02066285 Phase II trial is also testing 
pazopanib in patients with unresectable or met-
astatic solitary fibrous tumor and extraskeletal 
myxoid chondrosarcoma. Regorafenib is another 
oral multikinase inhibitor, which targets angio-
genic, stromal and oncogenic RTKs and is cur-
rently being tested in a Phase II study in patients 
with metastatic bone sarcomas (NCT02389244).
Other targeted treatments
Estrogen receptors are key regulators of the lon-
gitudinal skeletal growth that is initiated from 
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chondrocyte differentiation and proliferation in 
the epiphyseal growth plate of long bones [90]. 
Expression of estrogen and aromatase receptors 
has been identified in chondrosarcomas [90,91], 
suggesting that these tumors could be suscepti-
ble to estrogen and aromatase signaling inhibi-
tion [90]. However, in one study, in vitro and 
pilot in vivo studies showed no effect of any 
of the aromatase inhibitors on proliferation of 
co nventional chondrosarcomas [91].
The monoclonal antibody PRO95780 
(Genentech) is a proapoptotic receptor agonist, 
which specifically targets DR5, it activates 
the extrinsic apoptotic pathway and found 
to induce apoptosis in a plethora of human 
cancer cell lines and xenograft models [92,93]. 
PRO95780 targets DR5, which is expressed 
in a broad spectrum of hematologic malig-
nancies and solid tumors [94,95]. A Phase I 
study of PRO95780 in patients with advanced 
malignancies reported a minor response in a 
chondrosarcoma case [96], although an another 
Phase II study of PRO95780 in patients with 
advanced chondrosarcoma has been terminated 
Table 1. Registered clinical trials in chondrosarcoma.
Study ID Agent Mechanism of action Study design Study population Status
Targeting IDH mutations 
NCT02273739 AG-221 Oral IDH2 inhibitor Phase I/II Advanced solid tumors, 
including chondrosarcoma, 
and angioimmunoblastic T-cell 
lymphoma, with an IDH2 mutation
Ongoing, but 
not recruiting 
participants
NCT02481154 AG-881 Oral IDH inhibitor Phase I Advanced solid tumors, including 
chondrosarcoma, with an IDH1 and/
or IDH2 mutation
Recruiting
NCT02073994 AG-120 Oral IDH inhibitor Phase I Advanced solid tumors, including 
chondrosarcoma, with an IDH1 
mutation
Recruiting
NCT02496741 Metformin plus 
chloroquine
Oral antidiabetic (metformin) 
and oral antimalarial
Phase Ib IDH1/2 mutated patients 
with a glioma, intrahepatic 
cholangiocarcinoma or 
chondrosarcoma.
Recruiting
PI3K–Akt–mTOR pathway
NCT02008019 Everolimus mTOR inhibitor Phase II Neo-adjuvant therapy in patients 
with primary or relapsed 
chondrosarcomas
Recruiting
NCT00720174 Cixutumumab 
plus doxorubicin 
hydrochloride
IGF-1R inhibitor Phase I Patients with unresectable, locally 
advanced, or metastatic soft tissue 
sarcoma
Completed
NCT00928525 Imatinib A multi tyrosine kinase 
inhibitor including inhibition 
of PDGFR
Phase II Patients with advanced desmoid 
tumor and chondrosarcoma 
expressing the PDGFR-α and -β
Ongoing, but 
not recruiting 
participants
HDAC inhibitors
NCT00112463 Romidepsin Histone deacetylase inhibitor Phase II Patients with metastatic or 
unresectable soft tissue sarcoma
Unknown
Targeting angiogenesis
NCT01330966 Pazopanib Selective multi-targeted 
receptor tyrosine kinase 
inhibitor
Phase II Unresectable or metastatic 
chondrosarcoma
Ongoing, but 
not recruiting 
participants
NCT02066285 Pazopanib Selective multi-targeted 
receptor tyrosine kinase 
inhibitor
Phase II Patients with unresectable 
or metastatic solitary fibrous 
tumor and extraskeletal myxoid 
chondrosarcoma
Recruiting
NCT02389244 Regorafenib Multi-kinase inhibitor, which 
targets angiogenic, stromal 
and oncogenic receptor 
tyrosine kinase
Phase II Patients with metastatic bone 
sarcomas, including intermediate or 
high-grade chondrosarcomas
Recruiting
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due to lack of eff icacy in this population 
(NCT00543712).
INI-1/hSNF5 is a tumor suppressor gene, 
encoding a subunit of the SWI/SNF chroma-
tin remodeling complex and is widely expressed 
in most normal cells. Mutations or deletions of 
INI-1/hSNF5 have been described in malignant 
rhabdoid tumors and epithelioid sarcomas, 
including extraskeletal myxoid chondrosarco-
mas [97]. The histone-lysine N-methyltransferase 
enzyme EZH2 is encoded by the EZH2 gene 
and is involved in suppressing gene expres-
sion through methylation of H3K27. EZH2 
mutations or overexpressions are implicated in 
tumorigenesis of various cancers and correlate 
with poor prognosis thus, EZH2 has been an 
attractive target for anticancer therapy [98]. 
The EZH2 inhibitor, Tazemetostat is under 
clinical evaluation in a Phase II study, enroll-
ing adult patients with INI1-negative tumors 
– including extraskeletal myxoid chondrosar-
comas or relapsed/refractory synovial sarcoma 
(NCT02601950). Additionally, tazemetostat is 
being tested in a Phase I study of pediatric popu-
lation with relapsed or refractory INI1-negative 
tumors or synovial sarcoma (NCT02601937).
Immunotherapy with immune checkpoint 
inhibition is an area of interest that is currently 
being elucidated in numerous malignancies, 
including sarcoma. PD-1 and its ligand (PD-
L1) are key suppressors of the cytotoxic immune 
response, and their interaction results in a down-
regulation of the T-cell response. Blockade of the 
interaction between PD-1 and PD-L1 has been 
reported to have impressive antitumor effect. 
Kostine et al. reported an analysis of PD-L1 
protein expression in a series of conventional, 
mesenchymal, clear cell and dedifferentiated 
chondrosarcomas [99]. Only dedifferentiated 
chondrosarcomas displayed PD-L1 positivity, 
which in association with immune-infiltrating 
cells and HLA class I expression in nearly 50% of 
the dedifferentiated chondrosarcomas provided 
rationale for testing PD-1/PD-L1-targeted thera-
pies in these patients [99]. Preliminary results of 
a Phase II study (SARC028) of the anti-PD1 
antibody pembrolizumab (MK-3475) in patients 
with advanced soft tissue and bone sarcomas 
showed that 33% of patients with undifferen-
tiated pleomorphic sarcoma and dedifferenti-
ated liposarcoma had a tumor size shrinkage, 
while one out of the six patients enrolled with 
dedifferentiated chondrosarcoma exhibited par-
tial tumor remission. These results imply that 
further investigations are warranted in these 
sarcoma types [100].
Conclusion
The past few years research focused on eluci-
dating the molecular events underlying the 
pathogenesis of chondrosarcoma has led to the 
identification of several new potential therapeu-
tic targets. Most of these targets demonstrated 
meaningful antitumor activity in preclinical 
studies, although the results in early phase clini-
cal studies has been inconsistent. Future stud-
ies should further explore the utility of these 
candidate molecularly targeted therapies in the 
 different subgroups of chondrosarcoma patients.
Future perspective
As previously described, chondrosarcoma has 
a diverse pattern behavior, ranging from slow-
growing nonmetastasizing lesions to aggres-
sive metastasizing sarcomas. In the past, the 
modalities that were used to treat these rare 
tumors were surgical resection, as the mainstay 
of treatment and chemo-radiotherapy with 
rather discouraging results. In our site (The 
Royal Marsden Hospital, Sarcoma Unit), we 
have treated ten patients with antiangiogenic 
agents with durable disease stabilization, in 
patients with previously progressing metastatic 
disease. We are currently in the process of pub-
lishing this case series, although further work 
with these agents is clearly needed. As it is cru-
cial to identify and develop effective adjuvant 
treatments, the results of the current research 
are being awaited with great interest, so as to 
achieve in the future a better clinical outcome 
to this rare entity.
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EXECUTivE SUMMARY
 ●  Chondrosarcoma displays diverse histopathology and clinical behavior. The clinical management is exceptionally 
challenging as they are inherently resistant to conventional chemo and radiation therapy, therefore new therapeutic 
approaches are urgently needed.
The emerging role of IDH mutations in chondrosarcoma
 ●  Preclinical data indicate antitumor activity of IDH inhibitors in chondrosarcoma cell lines. Ongoing early phase clinical 
trials are evaluating the clinical activity of novel IDH inhibitors in patients with advanced solid tumors, including 
chondrosarcoma with an IDH1 and/or IDH2 mutation.
Targeting the hedgehog pathway
 ●  Emerging evidence proposes constitutive Indian Hedgehog signaling to have a key role in the pathogenesis of 
chondrosarcomas. However, the clinical data of a Phase II trial of IPI-926 (saridegib) in patients with advanced 
chondrosarcoma have been discouraging, although preclinical data have demonstrated activity in a wide range of 
malignancies.
The SRC pathway
 ●  Src has been proposed to play an important role in signal transduction in human sarcomas and a number of Src 
inhibitors, including dasatinib (BMS354825) are currently at various stages in the development process.
 ●  Dasatinib has shown some preclinical activity in chondrosarcomas as a single agent, but there is, also, evidence to 
support the use of dasatinib in combination with other antineoplastic drugs, for example, doxorubicin.
Targeting the PI3K–Akt–mTOR pathway
 ●  Preclinical data indicate that inhibition of the PI3K/Akt/mTOR pathway has suppressant effect on chondrosarcoma 
tumor progression.
 ●  Several early phase clinical trials are evaluating the combined mTORC1 and IGF-1R inhibition in sarcoma patients, with 
early results indicating that the combination may have greater clinical efficacy than treatment with each agent alone.
Histone deacetylase inhibitors
 ●  Preclinical data show that histone deacetylase inhibitors induce growth arrest, apoptosis and differentiation in 
sarcoma cancer stem cells, as well as in chondrosarcoma cells. There is an ongoing Phase II clinical trial of the histone 
deacetylase inhibitors Romidepsin in metastatic or unresectable soft tissue sarcomas (NCT00112463).
The role of angiogenesis
 ●  Evidence from preclinical data implicates angiogenesis with the pathogenesis of chondrosarcomas, while angiogenesis 
inhibitors show tumor growth inhibition in chondrosarcoma animal models and cell lines.
Future perspective
 ●  A plethora of molecularly targeted therapies are under clinical evaluation in patients with chondrosarcoma, aiming to 
a more personalized and effective treatment approach.
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